Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 5042-5050 |
| Number of pages | 9 |
| Journal | Vaccine |
| Volume | 33 |
| Issue number | 39 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Cite this
}
Reduced dose human papillomavirus vaccination : An update of the current state-of-the-art. / Toh, Zheng Quan; Licciardi, Paul; Fong, James; Garland, Suzanne; Tabrizi, Sepehr; Russell, Fiona; MULHOLLAND, Edward (Kim).
In: Vaccine, Vol. 33, No. 39, 2015, p. 5042-5050.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Reduced dose human papillomavirus vaccination
T2 - An update of the current state-of-the-art
AU - Toh, Zheng Quan
AU - Licciardi, Paul
AU - Fong, James
AU - Garland, Suzanne
AU - Tabrizi, Sepehr
AU - Russell, Fiona
AU - MULHOLLAND, Edward (Kim)
PY - 2015
Y1 - 2015
N2 - Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed.
AB - Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 years of age, provided the 2nd dose is given 6 months apart. Although reduced dose schedules can alleviate costs and logistics associated with HPV vaccination, especially in resource-poor countries, there are still gaps in this area of research, particularly regarding long-term protection. This review discusses the findings on antibody response and clinical outcomes in studies evaluating reduced dose HPV schedules, and highlights the important considerations of its implementation. In addition, other important immunological biomarkers that may be associated with long-term protection are highlighted and discussed.
KW - Wart virus vaccine
KW - antibody response
KW - comparative study
KW - drug dose regimen
KW - human
KW - immune response
KW - immunological parameters
KW - papillomavirus infection
KW - priority journal
KW - Review
KW - treatment outcome
KW - vaccination
KW - world health organization
U2 - 10.1016/j.vaccine.2015.07.102
DO - 10.1016/j.vaccine.2015.07.102
M3 - Article
VL - 33
SP - 5042
EP - 5050
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 39
ER -